Clinical Takeaway
In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability compared to placebo, suggesting CBD may not have meaningful direct anti-epileptic properties on its own. This supports the hypothesis that CBD’s seizure-reducing benefits in conditions like Dravet syndrome and Lennox-Gastaut syndrome are largely driven by its pharmacokinetic interaction with clobazam rather than a direct brain effect. Clinically, this reinforces that CBD’s role in epilepsy management is best understood within the context of combination therapy, not as a standalone cortical stabilizer.
#9 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure disorders may depend primarily on pharmacokinetic interactions with concurrent antiepileptic drugs rather than direct effects on neuronal excitability, fundamentally changing how clinicians should interpret its mechanism of action and therapeutic role. Understanding that CBD lacks direct cortical effects has important implications for monotherapy considerations and for predicting efficacy when CBD is combined with different ASM regimens. These findings suggest that CBD’s clinical benefit in approved indications likely results from drug-drug interactions rather than intrinsic anticonvulsant properties, which could reshape future treatment algorithms and polypharmacy strategies in epilepsy management.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover trial provides useful mechanistic clarity by demonstrating that CBD’s seizure-reducing effects in approved indications likely stem from drug-drug interactions rather than direct suppression of cortical excitability, a finding that challenges some assumptions about how CBD works as monotherapy. The study’s rigor is notable, though the generalizability to patients with comorbid conditions, polypharmacy patterns, or the specific seizure syndromes for which CBD is approved remains an important caveat. Notably, the absence of direct cortical effects does not diminish CBD’s clinical utility in conditions like Dravet or Lennox-Gastaut syndrome, where its interaction with clobazam appears to be therapeutically meaningful. For practitioners, this evidence suggests that when prescribing CBD for seizure disorders, attention to concurrent medications and potential pharmacokinetic interactions is more critical than relying on a theoretical direct anticonvulsant mechanism, and caution is warranted before extrapolating efficacy to off-